200 related articles for article (PubMed ID: 18057232)
41. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.
Prince S; Keating S; Fielding C; Brennan P; Floettmann E; Rowe M
J Virol; 2003 Apr; 77(8):5000-7. PubMed ID: 12663807
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
Incrocci R; McCormack M; Swanson-Mungerson M
J Gen Virol; 2013 May; 94(Pt 5):1127-1133. PubMed ID: 23303827
[TBL] [Abstract][Full Text] [Related]
43. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).
Rochford R; Miller CL; Cannon MJ; Izumi KM; Kieff E; Longnecker R
Arch Virol; 1997; 142(4):707-20. PubMed ID: 9170499
[TBL] [Abstract][Full Text] [Related]
44. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
[TBL] [Abstract][Full Text] [Related]
45. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.
Longnecker R; Kieff E
J Virol; 1990 May; 64(5):2319-26. PubMed ID: 2157888
[TBL] [Abstract][Full Text] [Related]
46. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.
Fish K; Comoglio F; Shaffer AL; Ji Y; Pan KT; Scheich S; Oellerich A; Doebele C; Ikeda M; Schaller SJ; Nguyen H; Muppidi J; Wright GW; Urlaub H; Serve H; Staudt LM; Longnecker R; Oellerich T
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26318-26327. PubMed ID: 33020271
[TBL] [Abstract][Full Text] [Related]
47. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.
Fruehling S; Lee SK; Herrold R; Frech B; Laux G; Kremmer E; Grässer FA; Longnecker R
J Virol; 1996 Sep; 70(9):6216-26. PubMed ID: 8709248
[TBL] [Abstract][Full Text] [Related]
48. Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.
Nawandar DM; Ohashi M; Djavadian R; Barlow E; Makielski K; Ali A; Lee D; Lambert PF; Johannsen E; Kenney SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179525
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review.
Ribeiro J; Oliveira C; Malta M; Sousa H
Future Oncol; 2017 Mar; 13(6):567-579. PubMed ID: 28118740
[TBL] [Abstract][Full Text] [Related]
50. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
51. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
Ikeda M; Ikeda A; Longnecker R
J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
[TBL] [Abstract][Full Text] [Related]
52. Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.
Fukuda M; Kawaguchi Y
J Virol; 2014 May; 88(9):5189-94. PubMed ID: 24554661
[TBL] [Abstract][Full Text] [Related]
53. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction.
Fruehling S; Longnecker R
Virology; 1997 Sep; 235(2):241-51. PubMed ID: 9281504
[TBL] [Abstract][Full Text] [Related]
54. LMP2A does not require palmitoylation to localize to buoyant complexes or for function.
Katzman RB; Longnecker R
J Virol; 2004 Oct; 78(20):10878-87. PubMed ID: 15452208
[TBL] [Abstract][Full Text] [Related]
55. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
56. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.
Guasparri I; Bubman D; Cesarman E
Blood; 2008 Apr; 111(7):3813-20. PubMed ID: 18230756
[TBL] [Abstract][Full Text] [Related]
57. Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.
Tomaszewski-Flick MJ; Rowe DT
Virus Genes; 2007 Oct; 35(2):225-34. PubMed ID: 17564822
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
Cooper L; Longnecker R
Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
[TBL] [Abstract][Full Text] [Related]
59. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
[TBL] [Abstract][Full Text] [Related]
60. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines.
Chen F; Liu C; Lindvall C; Xu D; Ernberg I
Int J Cancer; 2005 Jan; 113(2):284-9. PubMed ID: 15389515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
